The other NMA, which included five randomized controlled trials (RCTs) (Keynote 040 and 048, Eagle, Checkmate 141, and Condor), compared anti-PD-1 to anti-PD-L1 therapies in HNSCC [19]. Here, CD274 is linked to head and neck squamous cell carcinoma.